SCHEMBL10022346

SCHEMBL10022346

CC(C)c1ccc(N2CCS(=O)(=O)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 5/20 0.53
KDM5B Q9UGL1 1/20 0.45
MAPT P10636 6/20 0.45
LMNA P02545 2/20 0.44
PANK3 Q9H999 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MAPK1 P28482 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
GAA P10253 3/20 0.43
ALOX15 P16050 2/20 0.43
ALOX12 P18054 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
RORC P51449 2/20 0.43
MGLL Q99685 1/20 0.43
TP53 P04637 2/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9888688 0.86 KDM4E (0.56) KDM4EALDH1A1KDM5BMAPTLMNA
SCHEMBL20251137 0.82 MAPT (0.51) KDM4EALDH1A1MAPTLMNAPANK3
SCHEMBL12219412 0.82 KDM4E (0.51) KDM4EALDH1A1KDM5BMAPTL3MBTL1
SCHEMBL10022373 0.80 NOTUM (0.51) KDM4EALDH1A1PANK3HRH3
SCHEMBL19063587 0.79 KDM4E (0.45) KDM4EALDH1A1KDM5BMAPTPANK3
SCHEMBL101926 0.79 ALDH1A1 (0.64) KDM4EALDH1A1MAPTLMNAPANK3
SCHEMBL10001302 0.79 KDM4E (0.59) KDM4EALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL175496 0.79 KDM4E (0.59) KDM4EALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL12551114 0.79 KDM4E (0.59) KDM4EALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL18118174 0.78 HPGD (0.52) KDM4EALDH1A1MAPTLMNAPANK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 US disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-11230571-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-01-25 US disclosed
EP-3922639-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2021-12-15 EP disclosed
EP-3298027-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2021-04-28 EP disclosed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US disclosed
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2020-11-12 US disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 US disclosed
US-20120225855-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS ZHU BING-YAN (US) 2012-09-06 US disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
WO-2012006203-A1 N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-12 WO disclosed
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods GENENTECH, INC. 2010-02-25 US disclosed
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods GENENTECH, INC. 2010-02-25 US disclosed
US-20100035875-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. 2010-02-11 US disclosed
US-20090317360-A1 ANTI-VIRAL INHIBITORS AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-12-24 US disclosed
US-20090317360-A1 ANTI-VIRAL INHIBITORS AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 KDM4E 2228/4885ALDH1A1 2924/4885KDM5B 2483/4885
US-20100048557-A1 Triazolopyridine JAK Inhibitor Compounds and Methods JAK2, JAK1, JAK3 KDM4E 2916/4885ALDH1A1 2375/4885KDM5B 2363/4885
US-11382949-B2 Anthelmintic depsipeptide compounds ENPP2, ROCK2, RRP12 KDM4E 2237/4885ALDH1A1 3183/4885KDM5B 1286/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP KDM4E 1200/4885ALDH1A1 3037/4885KDM5B 916/4885
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT KDM4E 2606/4885ALDH1A1 2193/4885KDM5B 2387/4885
US-10975084-B2 KDM5 inhibitors KDM5A, KDM5B, KDM5C KDM4E 11/4885ALDH1A1 1399/4885KDM5B 2/4885
US-20120225855-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KDM4E 2916/4885ALDH1A1 2375/4885KDM5B 2363/4885
US-20120165322-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA KDM4E 2031/4885ALDH1A1 2674/4885KDM5B 1817/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP KDM4E 1071/4885ALDH1A1 2890/4885KDM5B 806/4885
US-20090317360-A1 ANTI-VIRAL INHIBITORS AND METHODS OF USE ACE, SARS1, ACE2 KDM4E 2823/4885ALDH1A1 1957/4885KDM5B 3303/4885
US-20100035875-A1 TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KDM4E 2916/4885ALDH1A1 2375/4885KDM5B 2363/4885
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP KDM4E 1200/4885ALDH1A1 3037/4885KDM5B 916/4885
US-11230571-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP KDM4E 1071/4885ALDH1A1 2890/4885KDM5B 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.